摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-3-[4-[[(3S)-3-[(3-cyclopentyl-1-methyl-2-pyridin-2-ylindole-6-carbonyl)amino]-1-methylpyrrolidine-3-carbonyl]amino]phenyl]prop-2-enoic acid | 494854-47-6

中文名称
——
中文别名
——
英文名称
(E)-3-[4-[[(3S)-3-[(3-cyclopentyl-1-methyl-2-pyridin-2-ylindole-6-carbonyl)amino]-1-methylpyrrolidine-3-carbonyl]amino]phenyl]prop-2-enoic acid
英文别名
——
(E)-3-[4-[[(3S)-3-[(3-cyclopentyl-1-methyl-2-pyridin-2-ylindole-6-carbonyl)amino]-1-methylpyrrolidine-3-carbonyl]amino]phenyl]prop-2-enoic acid化学式
CAS
494854-47-6
化学式
C35H37N5O4
mdl
——
分子量
591.71
InChiKey
HKEIFAYRXLUISG-FXIAJICWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    44
  • 可旋转键数:
    8
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    117
  • 氢给体数:
    3
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    6-吲哚甲酸copper(l) iodide正丁基锂 、 20% Pd(OH)2/C 、 氢气sodium acetatepotassium carbonate三苯基膦lithium chloride 、 potassium hydroxide 、 sodium hydroxide 作用下, 以 四氢呋喃甲醇正己烷醋酸异丙酯二甲基亚砜N,N-二甲基甲酰胺 为溶剂, -72.0~100.0 ℃ 、101.33 kPa 条件下, 反应 47.75h, 生成 (E)-3-[4-[[(3S)-3-[(3-cyclopentyl-1-methyl-2-pyridin-2-ylindole-6-carbonyl)amino]-1-methylpyrrolidine-3-carbonyl]amino]phenyl]prop-2-enoic acid
    参考文献:
    名称:
    Discovery of the First Thumb Pocket 1 NS5B Polymerase Inhibitor (BILB 1941) with Demonstrated Antiviral Activity in Patients Chronically Infected with Genotype 1 Hepatitis C Virus (HCV)
    摘要:
    Combinations of direct acting antivirals (DAAs) that have the potential to suppress emergence of resistant virus and that can be used in interferon-sparing regimens represent a preferred option for the treatment of chronic HCV infection. We have discovered allosteric (thumb pocket 1) non-nucleoside inhibitors of HCV NS5B polymerase that inhibit replication in replicon systems. Herein, we report the late-stage optimization of indole-based inhibitors, which began with the identification of a metabolic liability common to many previously reported inhibitors in this series. By use of parallel synthesis techniques, a sparse matrix of inhibitors was generated that provided a collection of inhibitors satisfying potency criteria and displaying improved in vitro ADME profiles. "Cassette" screening for oral absorption in rat provided a short list of potential development candidates. Further evaluation led to the discovery of the first thumb pocket 1 NS5B inhibitor (BILB 1941) that demonstrated antiviral activity in patients chronically infected with genotype 1 HCV.
    DOI:
    10.1021/jm3006788
点击查看最新优质反应信息

文献信息

  • Viral polymerase inhibitors
    申请人:Beaulieu Louis Pierre
    公开号:US20060160798A1
    公开(公告)日:2006-07-20
    An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR 1 , or CR 1 , wherein R 1 is defined herein; represents either a single or a double bond; R 2 is selected from 6 or 10-membered aryl and Het, each optionally substituted with R 20 ; provided that Het is not a 5- or 6-membered monocyclic heterocycle having 1 or 2 nitrogen heteroatoms; B is NR 3 or CR 3 , with the proviso that one of A or B is either CR 1 or CR 3 , wherein R 3 is defined herein; K is N or CR 4 , wherein R 4 is defined herein; L is N or CR 5 , wherein R 5 has the same definition as R 4 ; M is N or CR 7 , wherein R 7 has the same definition as R 4 ; Y 1 is O or S; Z is N(R 6a )R 6 or OR 6 , wherein R 6a is H or alkyl or NR 61 R 62 wherein R 61 and R 62 are defined herein; and R 6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R 6 is wherein R 7 and R 8 and Q are as defined herein; Y 2 is O or S; R 9 is H, (C 1-6 alkyl), (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl, aryl, Het, (C 1-6 )alkyl-aryl or (C 1-6 )alkyl-Het, all of which optionally substituted with R 90 ; or R 9 is covalently bonded to either of R 7 or R 8 to form a 5- or 6-membered heterocycle; a salt or a derivative thereof, as an inhibitor of HCV NS 5 B polymerase.
    化合物的异构体、对映异构体、非对映异构体或互变异构体,由式I表示:其中:A是O、S、NR1或CR1,其中R1的定义如下;表示单键或双键;R2选自6或10元芳基和Het,每个可选择用R20取代;但是,Het不是具有1或2个氮杂原子的5-或6元单环杂环;B是NR3或CR3,但其中A或B之一是CR1或CR3,其中R3的定义如下;K是N或CR4,其中R4的定义如下;L是N或CR5,其中R5的定义与R4相同;M是N或CR7,其中R7的定义与R4相同;Y1是O或S;Z是N(R6a)R6或OR6,其中R6a为H或烷基或NR61R62,其中R61和R62的定义如下;而R6是H、烷基、环烷基、烯基、Het、烷基-芳基、烷基-Het;或R6是其中R7和R8和Q的定义如下;Y2是O或S;R9是H、(C1-6烷基)、(C3-7环烷基)或(C1-6烷基-(C3-7)环烷基)、芳基、Het、(C1-6烷基-芳基)或(C1-6烷基-Het),所有这些都可以选择用R90取代;或者R9与R7或R8中的任一种共价键结合形成5-或6元杂环;作为HCV NS5B聚合酶的抑制剂,其盐或衍生物。
  • Viral Polymerase Inhibitors
    申请人:Beaulieu Pierre Louis
    公开号:US20090087409A1
    公开(公告)日:2009-04-02
    An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR 1 , or CR 1 , wherein R 1 is defined herein; represents either a single or a double bond; R 2 is selected from: H, halogen, R 21 , OR 21 , SR 21 , COOR 21 , SO 2 N(R 22 ) 2 , N(R 22 ) 2 , CON(R 22 ) 2 , NR 22 C(O)R 22 or NR 22 C(O)NR 22 wherein R 21 and each R 22 is defined herein; B is NR 3 or CR 3 , with the proviso that one of A or B is either CR 1 or CR 3 , wherein R 3 is defined herein; K is N or CR 4 , wherein R 4 is defined herein; L is N or CR 5 , wherein R 5 has the same definition as R 4 ; M is N or CR 7 , wherein R 7 has the same definition as R 4 ; Y 1 is O or S; Z is N(R 6a )R 6 or OR 6 , wherein R 6a is H or alkyl or NR 61 R 62 wherein R 61 and R 62 are defined herein; and R 6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R 6 is wherein R 7 and R 8 and Q are as defined herein; Y 2 is O or S; R 9 is H, (C 1-6 alkyl), (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl, aryl, Het, (C 1-6 )alkyl-aryl or (C 1-6 )alkyl-Het, all of which optionally substituted with R 90 ; or R 9 is covalently bonded to either of R 7 or R 8 to form a 5- or 6-membered heterocycle; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.
    化合物的同分异构体、对映异构体、非对映异构体或互变异构体,由公式I表示:其中:A为O、S、NR1或CR1,其中R1在此定义;表示单键或双键;R2选自:H、卤素、R21、OR21、SR21、COOR21、SO2N(R22)2、N(R22)2、CON(R22)2、NR22C(O)R22或NR22C(O)NR22,其中R21和每个R22在此定义;B为NR3或CR3,但A或B中的一个为CR1或CR3,其中R3在此定义;K为N或CR4,其中R4在此定义;L为N或CR5,其中R5具有与R4相同的定义;M为N或CR7,其中R7具有与R4相同的定义;Y1为O或S;Z为N(R6a)R6或OR6,其中R6a为H或烷基,或NR61R62,其中R61和R62在此定义;R6为H、烷基、环烷基、烯基、Het、烷基-芳基、烷基-Het;或R6为,其中R7、R8和Q在此定义;Y2为O或S;R9为H、(C1-6)烷基、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基、芳基、Het、(C1-6)烷基-芳基或(C1-6)烷基-Het,其中所有这些都可以选择地用R90取代;或R9与R7或R8中的任意一个共价键结合形成5-或6-成员杂环;其盐或衍生物,作为HCV NS5B聚合酶的抑制剂。
  • Hepatitis C virus polymerase inhibitors with a heterobicylic structure
    申请人:BOEHRINGER INGELHEIM (CANADA) LTD.
    公开号:EP2335700A1
    公开(公告)日:2011-06-22
    An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; ----- represents either a single or a double bond; R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, , CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5, wherein R5 has the same definition as R4; M is N or CR7, wherein R7 has the same definition as R4; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; and R6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R6 is wherein R7 and R8 and Q are as defined herein; Y2 is O or S; R9 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-aryl or (C1-6)alkyl-Het, all of which optionally substituted with R90; or R9 is covalently bonded to either of R7 or R8 to form a 5- or 6-membered heterocycle; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.
    式 I 所代表化合物的异构体、对映体、非对映异构体或同系物: 其中 A 是 O、S、NR1 或 CR1,其中 R1 在此定义; ----- 代表单键或双键; R2 选自:H、卤素、R21、OR21、SR21、COOR21、SO2N(R22)2、N(R22)2、CON(R22)2、 NR22C(O)R22 或 NR22C(O)NR22 其中 R21 和各 R22 在本文中定义; B 是 NR3 或 CR3,但 A 或 B 之一必须是 CR1 或 CR3、 其中 R3 在此定义; K 是 N 或 CR4,其中 R4 在本文中定义; L 是 N 或 CR5,其中 R5 的定义与 R4 相同; M 是 N 或 CR7,其中 R7 的定义与 R4 相同; Y1 是 O 或 S Z 是 N(R6a)R6 或 OR6,其中 R6a 是 H 或烷基或 NR61R62,其中 R61 和 R62 在本文中定义;以及 R6 是 H、烷基、环烷基、烯基、Het、烷基芳基、烷基-Het; 或 R6 是 其中 R7 和 R8 以及 Q 如本文所定义; Y2 是 O 或 S R9 是 H、(C1-6烷基)、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基、芳基、Het、(C1-6)烷基-芳基或(C1-6)烷基-Het,所有这些任选被 R90 取代;或 R9 与 R7 或 R8 其中之一共价键合形成 5 或 6 元杂环; 作为 HCV NS5B 聚合酶抑制剂的盐或其衍生物。
  • HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYLIC STRUCTURE
    申请人:BOEHRINGER INGELHEIM (CANADA) LTD.
    公开号:EP1414797B9
    公开(公告)日:2009-04-15
  • US7141574B2
    申请人:——
    公开号:US7141574B2
    公开(公告)日:2006-11-28
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物